CONGRATS TO WINTER BRAIN'S 2024 PIONEER AWARDEES!

Each year, Winter Brain solicits nominations for the annual Pioneer Awards. This tradition serves to recognize and honor pioneering scientists who demonstrate excellence in the field of neuroscience and have made invaluable contributions to Winter Brain over the years. Many worthy candidates were nominated this year and the Winter Brain Board of Directors and Executive Committee had the difficult task to select two candidates for recognition.

THOMAS M. HYDE, M.D, PH.D.

2024 Winter Brain Pioneer Awardee

Dr. Hyde received his combined MD-PhD degrees in 1984, and then completed a general medical internship at Presbyterian-University of Pennsylvania Medical Center. Following his internship, Dr. Hyde completed a residency in Neurology at Stanford University Hospital from 1985-1988, serving as chief resident of Neurology his last year of residency. He completed his board certification in General Neurology in 1990.

In 2010, Dr. Hyde left the NIMH to become the Chief Operating Officer of the Lieber Institute for Brain Development on the Johns Hopkins Medical Campus in Baltimore. The Lieber Institute is a non-profit biomedical research organization dedicated to finding the causes and cures for complex behavioral disorders including schizophrenia, bipolar disorder, and depression. He served as Chief Operating Officer from 2010-2016 before transitioning to Chief Medical Officer. While at the institute in 2012 he established the Lieber Institute Human Brain and Tissue Repository. In addition to his administrative work, Dr. Hyde has had an active research career in neuropsychiatry. He has published over 230 peer reviewed original scientific articles with a focus on the biology of mental illness and post-mortem human brain.



ANIL MALHOTRA, M.D.

2024 Winter Brain Pioneer Awardee

Dr. Anil Malhotra is the Co-Director of the Institute of Behavioral Science at the Feinstein Institutes for Medical Research in Manhasset, NY, Director of Psychiatry Research at the Zucker Hillside Hospital in Glen Oaks, NY, and Professor and Vice Chair of Research, Department of Psychiatry, The Zucker School of Medicine at Hofstra/Northwell in Hempstead, NY.

Dr. Malhotra completed his undergraduate studies at Cornell University in 1985 and received his M.D. from Wake Forest University in 1989. After residency training in psychiatry at Georgetown University, he completed a research fellowship at the National Institute of Mental Health (NIMH) of the National Institutes of Health (NIH), where he initiated a research program in pharmacogenetics. Following his tenure at NIMH, Dr. Malhotra moved to the Zucker Hillside Hospital and developed an internationally recognized molecular genetics program focused on the major neuropsychiatric disorders.

Dr. Malhotra's group has identified a number of genes associated with increased risk for schizophrenia, determined their relationship with important clinical manifestations of illness, including cognitive impairment, and examined the role of genetic factors in predicting individual responses to pharmacological treatment. His group published the first genome-wide association study (GWAS) of schizophrenia and found evidence for a role of specific genetic factors in vulnerability to antipsychotic drug-induced weight gain, a common yet potentially serious side effect of treatment.